Tue Sep 24 04:20:55 UTC 2024: ## Biotest Aktiengesellschaft Stock Drops 1% in Mid-Day Trading

**Frankfurt, Germany** – Biotest Aktiengesellschaft (ETR:BIO), a German pharmaceutical company specializing in clinical immunology, haematology, and intensive care medicine, saw its stock price decline by 1% in mid-day trading on Monday, September 24th, 2024. The stock reached a low of €41.60 ($46.22) before closing at €41.60 ($46.22). This represents a decrease from the previous day’s closing price of €42.00 ($46.67).

The trading volume for Biotest Aktiengesellschaft was significantly lower than average, with only 161 shares traded, a 92% drop from the usual daily volume of 1,927 shares.

Despite the decline in stock price, Biotest continues to hold a market cap of $823.26 million and a price-to-earnings ratio of 10.02. Its beta value stands at 0.24, indicating relatively low volatility compared to the broader market.

The company’s financial health appears strong, with a debt-to-equity ratio of 116.50, a quick ratio of 1.66, and a current ratio of 2.45. These ratios suggest a healthy liquidity position and ability to meet short-term obligations.

Biotest Aktiengesellschaft operates in the European Union, the Rest of the World, and Stateless segments. The company’s focus on therapeutic areas with high demand and its strong financial position could offer long-term growth potential.

Investors are advised to monitor the company’s performance and upcoming developments for further insights into its future trajectory.

Read More